CY2019026I1 - Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης - Google Patents

Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης

Info

Publication number
CY2019026I1
CY2019026I1 CY2019026C CY2019026C CY2019026I1 CY 2019026 I1 CY2019026 I1 CY 2019026I1 CY 2019026 C CY2019026 C CY 2019026C CY 2019026 C CY2019026 C CY 2019026C CY 2019026 I1 CY2019026 I1 CY 2019026I1
Authority
CY
Cyprus
Prior art keywords
reverse transcription
nucleoside inhibitors
nucleoside
inhibitors
transcription
Prior art date
Application number
CY2019026C
Other languages
English (en)
Other versions
CY2019026I2 (el
Original Assignee
Merck Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019026(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc. filed Critical Merck Canada Inc.
Publication of CY2019026I2 publication Critical patent/CY2019026I2/el
Publication of CY2019026I1 publication Critical patent/CY2019026I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
CY2019026C 2010-03-30 2019-05-16 Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης CY2019026I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07
PCT/CA2011/000320 WO2011120133A1 (en) 2010-03-30 2011-03-28 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
CY2019026I2 CY2019026I2 (el) 2020-05-29
CY2019026I1 true CY2019026I1 (el) 2020-05-29

Family

ID=44710363

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100114T CY1118774T1 (el) 2010-03-30 2017-01-25 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019025C CY2019025I1 (el) 2010-03-30 2019-05-16 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019026C CY2019026I1 (el) 2010-03-30 2019-05-16 Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20171100114T CY1118774T1 (el) 2010-03-30 2017-01-25 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019025C CY2019025I1 (el) 2010-03-30 2019-05-16 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης

Country Status (44)

Country Link
US (2) US8486975B2 (el)
EP (2) EP2552902B1 (el)
JP (2) JP5281718B2 (el)
KR (1) KR101421861B1 (el)
CN (1) CN102971308B (el)
AR (1) AR080859A1 (el)
AU (1) AU2011235568B2 (el)
BR (1) BR112012024691B1 (el)
CA (1) CA2794377C (el)
CL (1) CL2012002744A1 (el)
CO (1) CO6630126A2 (el)
CR (1) CR20120503A (el)
CY (3) CY1118774T1 (el)
DK (2) DK2924034T3 (el)
DO (1) DOP2012000256A (el)
EA (1) EA024804B1 (el)
EC (1) ECSP12012201A (el)
ES (2) ES2536295T3 (el)
FI (1) FIC20190021I1 (el)
GE (1) GEP20156368B (el)
HK (2) HK1175471A1 (el)
HN (1) HN2012002039A (el)
HR (2) HRP20150427T1 (el)
HU (4) HUE031785T2 (el)
IL (2) IL222030A (el)
LT (3) LT2924034T (el)
LU (2) LUC00113I9 (el)
MA (1) MA34170B1 (el)
ME (2) ME02181B (el)
MX (1) MX2012011379A (el)
MY (1) MY163979A (el)
NI (1) NI201200146A (el)
NL (1) NL300980I2 (el)
NO (2) NO2019018I1 (el)
NZ (1) NZ602670A (el)
PE (1) PE20130158A1 (el)
PL (2) PL2924034T3 (el)
PT (2) PT2552902E (el)
RS (2) RS54017B1 (el)
SG (1) SG184347A1 (el)
SI (2) SI2924034T1 (el)
TN (1) TN2012000455A1 (el)
TW (1) TWI458719B (el)
WO (1) WO2011120133A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02181B (me) * 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
BR112015005997A8 (pt) * 2012-09-26 2023-04-11 Merck Sharp & Dohme Composto
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
BR112015012843B8 (pt) * 2012-12-05 2023-04-25 Merck Sharp & Dohme Método para sintetizar o composto
EP3071037A4 (en) * 2013-11-22 2017-08-02 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
EP3617193B1 (en) 2013-12-04 2024-03-27 Merck Sharp & Dohme LLC Process for making reverse transcriptase inhibitors
DK3125894T3 (da) 2014-04-01 2020-11-16 Merck Sharp & Dohme Prodrugs af hiv-reverstranscriptasehæmmere
LT3383397T (lt) 2015-12-02 2021-11-25 Merck Sharp & Dohme Corp. Farmacinės kompozicijos, kurių sudėtyje yra doravirinas, tenofoviro dizoproksilo fumaratas ir lamivudinas
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
CA3060222A1 (en) 2017-04-18 2018-10-25 Cipla Limited Combination therapy for use in treating retroviral infections
CN112533613A (zh) 2018-02-06 2021-03-19 通用医疗公司 作为肿瘤免疫应答的生物标志物的重复rna
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
ATE448196T1 (de) 2004-04-23 2009-11-15 Hoffmann La Roche Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2006067587A2 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
RU2008119412A (ru) 2005-10-19 2009-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CA2705834A1 (en) * 2007-11-20 2009-05-28 Merck Sharp & Dohme Corp. Pyridinone non-nucleoside reverse transcriptase inhibitors
ME02181B (me) * 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze

Also Published As

Publication number Publication date
EP2552902B1 (en) 2015-03-11
DK2552902T3 (en) 2015-06-15
LTC2924034I2 (lt) 2020-10-12
EA024804B1 (ru) 2016-10-31
MX2012011379A (es) 2012-11-30
ES2536295T3 (es) 2015-05-22
ES2609636T3 (es) 2017-04-21
ME02181B (me) 2015-10-20
US20130296382A1 (en) 2013-11-07
US8486975B2 (en) 2013-07-16
JP5281718B2 (ja) 2013-09-04
NI201200146A (es) 2013-03-18
ME02570B (me) 2017-06-20
TW201139409A (en) 2011-11-16
TWI458719B (zh) 2014-11-01
EP2924034A1 (en) 2015-09-30
CA2794377C (en) 2015-06-16
EA201290976A1 (ru) 2013-03-29
SI2924034T1 (sl) 2017-05-31
JP2013209405A (ja) 2013-10-10
HK1209121A1 (en) 2016-03-24
LTC2552902I2 (lt) 2019-12-10
BR112012024691A2 (pt) 2019-07-02
RS54017B1 (en) 2015-10-30
EP2924034B1 (en) 2016-11-02
LUC00113I2 (el) 2024-05-22
CY2019026I2 (el) 2020-05-29
PL2924034T3 (pl) 2017-07-31
DK2924034T3 (en) 2017-02-06
IL233334A (en) 2015-09-24
CR20120503A (es) 2013-01-09
MA34170B1 (fr) 2013-04-03
HRP20161680T1 (hr) 2017-01-27
LUC00113I9 (el) 2024-06-07
US20110245296A1 (en) 2011-10-06
AU2011235568A1 (en) 2012-11-01
SI2552902T1 (sl) 2015-10-30
GEP20156368B (en) 2015-09-25
TN2012000455A1 (en) 2014-01-30
KR20120128703A (ko) 2012-11-27
CY1118774T1 (el) 2017-07-12
JP2013510800A (ja) 2013-03-28
CN102971308B (zh) 2015-02-04
CY2019025I2 (el) 2019-11-27
HUS1900022I1 (hu) 2019-05-28
CO6630126A2 (es) 2013-03-01
HK1175471A1 (en) 2013-07-05
BR112012024691B1 (pt) 2020-11-17
HUE031785T2 (en) 2017-08-28
CN102971308A (zh) 2013-03-13
LUC00114I1 (el) 2019-04-17
IL222030A (en) 2014-07-31
NL300980I1 (nl) 2019-04-24
DOP2012000256A (es) 2012-12-15
NO2019019I1 (no) 2019-04-24
EP2552902A1 (en) 2013-02-06
NL300980I2 (nl) 2021-06-17
NZ602670A (en) 2014-09-26
KR101421861B1 (ko) 2014-07-22
JP5886790B2 (ja) 2016-03-16
EP2552902A4 (en) 2013-09-04
HRP20150427T1 (hr) 2015-07-03
IL233334A0 (en) 2014-09-01
CY2019025I1 (el) 2019-11-27
MY163979A (en) 2017-11-15
LT2924034T (lt) 2016-12-27
AR080859A1 (es) 2012-05-16
CL2012002744A1 (es) 2012-12-14
PT2552902E (pt) 2015-06-02
HUS1900021I1 (hu) 2019-05-28
HN2012002039A (es) 2015-08-24
WO2011120133A1 (en) 2011-10-06
AU2011235568B2 (en) 2013-09-12
SG184347A1 (en) 2012-11-29
PL2552902T3 (pl) 2015-10-30
HUE025336T2 (en) 2016-03-29
LTPA2019506I1 (lt) 2019-04-25
CA2794377A1 (en) 2011-10-06
FIC20190021I1 (fi) 2019-04-17
LTPA2019507I1 (lt) 2019-04-25
PT2924034T (pt) 2017-01-06
ECSP12012201A (es) 2012-10-30
LUC00114I2 (el) 2020-07-10
NO2019018I1 (no) 2019-04-24
PE20130158A1 (es) 2013-02-28
RS55505B1 (sr) 2017-05-31

Similar Documents

Publication Publication Date Title
CY2019026I1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201600141B (it) Boronati quali inibitori di arginasi
SMT201500271B (it) Inibitori di neprilisina
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
BR112014000445A2 (pt) usos de inibidores de hsp90 marcados
BR112013016154A2 (pt) inibidores de faah
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
ZA201303433B (en) Inhibitors of hiv replication
BR112013012078A2 (pt) inibidores de nampt e rock
ZA201206456B (en) Uses of dgati inhibitors
BR112013025761A2 (pt) inibidores de hsp90
IL257069B (en) Inhibitors of cell death and uses thereof
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
DK2453858T3 (da) Fremgangsmåde
DK2516435T3 (da) Inhibitorer af AKT-aktivitet
FI20095315A0 (fi) Iskulaite
BR112013012958A2 (pt) inibidores integrin ligado com quinase
FI20105670A (fi) ABO-tyypin käyttö
FR2955136B1 (fr) Arret de vantail
UA21042S (uk) Комплект бланків
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
IT1400965B1 (it) Polimorfi di fexofenadina
DK2651404T3 (da) Caseinkinase-1 delta (ck1delta)-hæmmere